Particularly, since the FDA and EMA approval of MET inhibitors for NSCLCs with MET exon 14 skipping mutations, testing for all MET alterations, e.g., MET expression, MET mutations, MET gene amplifications, and MET fusions, should be routine standard of care for patients with NSCLC. The gene discussed is MET; the disease is non-small cell lung carcinoma.